None listed
Conditions
Brief summary
The purpose of this study is to determine the degree to which Docosahexaenoic acid (DHA) supplementation reduces the incidence of bronchopulomonary dysplasia (BPD), as assessed by the requirement for supplemental oxygen and/or assisted ventilation at 36 weeks post menstrual age.
Interventions
Tuna oil emulsion containing 120 mg/mL of DHA to provide 60 mg/kg/day of DHA (0.17 ml/kg three times a day). The intervention will be given enterally within 72 hours of the first enteral feed and continue until 36 weeks post menstrual age or discharge home (whichever occurs first).
Sponsors
South Australian Health and Medical Research Institute
Study design
Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Prevention
Masking
Blinded (masking used)
Eligibility
Sex/Gender
All
Age
0 to No maximum
Healthy volunteers
No
Inclusion criteria
Born at less than 29 weeks gestational age Within 3 days of commencing enteral feeds Has a legally acceptable representative capable of understanding the informed consent document and providing consent on the infant’s behalf
Exclusion criteria
Infants who have a major congenital or chromosomal abnormality will be excluded from the study Women providing breast milk who are taking supplements providing >250 mg DHA per day and do not wish to stop taking supplements. Infants participating in another fatty acid study. Infants receiving intravenous lipid emulsions containing fish oil given as early lipid parenteral nutrition support.
Outcome results
None listed